Shared by James Harvey
(ISSUP staff) - 1 July 2024
Format
Report
Published by / Citation
UNODC
A global reference on drug markets, trends and policy developments, the World Drug Report offers a wealth of data and analysis and in 2024 comprises several elements tailored to different audiences.
The Cannabis, Mental Health, and Substance Use Health: Research Knowledge Exchange Event Summary Report presents the findings and themes discussed at an event jointly hosted by CCSA (Canadian Centre on Substance Use and Addiction) and the Mental Health Commission of Canada. With funding from Health Canada, the two organizations supported approximately 70 research teams in exploring the potential benefits, harms, and risks of cannabis on substance use health and mental health. The event provided a platform for these research teams to share their project results, observations, and experiences...
SAMHSA report discusses the evidence supporting the effectiveness of screening, brief intervention, and referral to treatment (SBIRT) as a comprehensive approach, as well as for the implementation and effectiveness of the individual components of SBIRT for different behavioural health conditions.
The report describes briefly the underlying research that has been conducted in the prevention and early intervention of risky alcohol, substance abuse and tobacco consumption, as well as commonly reported mental health problems, and describes existing studies/models for specific populations and...
The ASSIST package, which consists of a brief questionnaire, a guide for health professionals on how to use the questionnaire in detecting and responding to substance use and also a self-help manual for cutting down or stopping substance use, is the result of more than 10-years work by WHO and an international group of researchers in the framework of the WHO ASSIST project. It is WHO’s response to the growing demand for guidance on how to best manage problems of substance use in non specialist health care settings. This approach, quick and easy to learn, useful for all substances including...
Call for Research Poster Abstract Submissions and Travel Award Requests
Submission Deadline: January 14, 2024
Present your international drug use and addiction research during the 2024 NIDA International Forum, which will be held June 14–17, 2024, in Montreal, Canada.
The NIDA International Program invites research poster abstract submissions and travel award applications from researchers around the world. Join for the Forum research symposium, interactive workshops, the poster session, and networking activities.
Recent research has revealed an increase in child hospitalisations resulting from accidental cannabis poisoning in various regions of Canada. Toddlers find cannabis edibles enticing due to their resemblance to common treats like candies, chocolates, or baked goods. Incidents of cannabis poisoning predominantly occur within households. It is imperative to emphasise the potential harm cannabis products can pose to children and the necessity of secure storage.
The Canadian Centre on Substance Use and Addiction (CCSA) initiated a public awareness campaign through its social media platforms. We...
This publication answers some of the more frequently asked questions raised in discussions about cannabis legislation. While the primary focus is on the use of cannabis for recreational purposes, relevant legislation for other uses, including medical and commercial cannabis-derived products such as cosmetics, wellness products and foods, is included in order to provide the necessary context for various policy initiatives.
The event is jointly organized by the United Nations Office on Drug and Crime (UNODC) Civil Society Unit and the Vienna NGO Committee on Drugs (VNGOC).
Ms Chloe Carpientier (Chief, UNODC Drugs Research Section) will present the main...
Of all illicit substances, cannabis stands out as the most extensively cultivated, trafficked, and misused. It has significant effects on the human body and mind, altering sensory perceptions, mood, cognitive abilities, motor coordination, and sense of self and time. In this reading list, you can find out more about cannabis and cannabis use. You can also visit the ISSUP network dedicated to the topic for further reading materials and resources.
1) The alcohol and drug foundation have put together a factsheet on cannabis, which provides a definition, information about how it is used, the...
Hasin, D., & Walsh, C. (2020). Cannabis use, cannabis use disorder, and comorbid psychiatric illness: a narrative review. Journal of Clinical Medicine, 10(1), 15.
Abstract
As attitudes toward cannabis, its legal status, and patterns of use continue to evolve, the landscape surrounding this substance is in a constant state of flux. Against this backdrop, this review aims to provide an up-to-date overview of the literature on the comorbidity of cannabis use and cannabis use disorder (CUD) with other substance use and psychiatric disorders.
Results:
A strong body of literature shows associations between cannabis use and CUD with other drug use, psychosis, mood disorders, anxiety disorders, and personality disorders.
Belete, H., Mekonen, T., Espinosa, D. C., Ambaw, F., Connor, J., Chan, G., ... & Leung, J. (2023). Cannabis use in Sub‐Saharan Africa: a systematic review and meta‐analysis. Addiction.
Abstract
Background and Aims
The most available data on the prevalence of cannabis use come from population surveys conducted in high-income countries in North America, Oceania and Europe. Less is known about the prevalence of cannabis use in Africa. This systematic review aimed to summarize general population-level cannabis use in sub-Saharan Africa since 2010.
Results
The study included 53 studies and included 13 239 participants.
Among adolescents, the life-time, 12-month and 6-month prevalence of cannabis use were 7.9%, 5.2% and 4.5% respectively.
Mills, L., Dunlop, A., Montebello, M. et al. Correlates of treatment engagement and client outcomes: results of a randomised controlled trial of nabiximols for the treatment of cannabis use disorder. Subst Abuse Treat Prev Policy 17, 67 (2022).
Introduction
There is increasing interest and evidence for the use of cannabinoid medications in the treatment of cannabis use disorder, but little examination of the correlates of successful treatment. This paper is a secondary analysis of a randomised placebo-controlled trial of nabiximols for the treatment of cannabis use disorder (CUD), aiming to identify which client and treatment characteristics impact treatment engagement and outcomes.
Method
Bayesian multiple regression models were used to examine the impact of age, gender, duration of regular cannabis use, daily quantity of...
Mills, L., Dunlop, A., Montebello, M. et al. Correlates of treatment engagement and client outcomes: results of a randomised controlled trial of nabiximols for the treatment of cannabis use disorder. Subst Abuse Treat Prev Policy 17, 67 (2022). https://doi.org/10.1186/s13011-022-00493-z
Introduction and aims
There is increasing interest and evidence for the use of cannabinoid medications in the treatment of cannabis use disorder, but little examination of the correlates of successful treatment. This paper is a secondary analysis of a randomised placebo-controlled trial of nabiximols for the treatment of cannabis use disorder (CUD), aiming to identify which client and treatment characteristics impact treatment engagement and outcomes.
Method
Bayesian multiple regression models were used to examine the impact of age, gender, duration of regular cannabis use, daily...
ISSUP Chile invites you to participate in a webinar on the results of current research on the impact of cannabis use on the developing adolescent brain?
The webinar will take place on Thursday, November 10, 2022 at 17:30 (Chile time)
Imtiaz, S., Wells, S., Rehm, J. et al. Daily cannabis use during the novel coronavirus disease (COVID-19) pandemic in Canada: a repeated cross-sectional study from May 2020 to December 2020. Subst Abuse Treat Prev Policy 17, 14 (2022). https://doi.org/10.1186/s13011-022-00441-x
The novel coronavirus disease (COVID-19) pandemic has resulted in substantial burden of disease in Canada. Daily cannabis use is most strongly implicated in the cannabis-attributable burden of disease. In the context of the novel coronavirus disease (COVID-19) pandemic in Canada, the trends were characterised in daily cannabis use in the overall sample and various population subgroups, and examined risk characteristics associated with daily cannabis use.
The specific objectives of this study were as follows:
Characterise trends in daily cannabis use in the overall sample and various...